Angiotensin II | CAS#4474-91-3 | vasoconstrictor peptide

MedKoo Cat#: 522373 | Name: Angiotensin II

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Angiotensin II is an endogenous potent vasoconstrictor peptide. The amino acid sequence of angiotensin II is Asp-Arg-Val-Tyr-Ile-His-Pro-Phe | His-Leu. Angiotensin II increases blood pressure by stimulating the Gq protein in vascular smooth muscle cells (which in turn activates an IP3-dependent mechanism leading to a rise in intracellular calcium levels and ultimately causing contraction). In addition, angiotensin II acts at the Na/H exchanger in the proximal tubules of the kidney to stimulate Na reabsorption and H excretion which is coupled to bicarbonate reabsorption. This ultimately results in an increase in blood volume, pressure, and pH. Angiotensin II is degraded to angiotensin III by angiotensinases located in red blood cells and the vascular beds of most tissues. It has a half-life in circulation of around 30 seconds, whereas, in tissue, it may be as long as 15–30 minutes.

Chemical Structure

Angiotensin II

CAS#4474-91-3

Theoretical Analysis

MedKoo Cat#: 522373

Name: Angiotensin II

CAS#: 4474-91-3

Chemical Formula: C50H71N13O12

Exact Mass: 1045.5345

Molecular Weight: 1046.20

Elemental Analysis: C, 57.40; H, 6.84; N, 17.41; O, 18.35

Price and Availability

Size	Price	Availability
5mg	USD 450.00	2 Weeks
25mg	USD 950.00	2 Weeks
100mg	USD 1,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Angiotensin II; Asp-Arg-Val-Tyr-Ile-His-Pro-Phe.

IUPAC/Chemical Name

(2S,5S,8S,11S,14S,17S)-2-((1H-imidazol-5-yl)methyl)-17-amino-5-((S)-sec-butyl)-1-((S)-2-(((S)-1-carboxy-2-phenylethyl)carbamoyl)pyrrolidin-1-yl)-14-(3-((diaminomethylene)amino)propyl)-8-(4-hydroxybenzyl)-11-isopropyl-1,4,7,10,13,16-hexaoxo-3,6,9,12,15-pentaazanonadecan-19-oic acid

InChi Key

CZGUSIXMZVURDU-JZXHSEFVSA-N

InChi Code

InChI=1S/C50H71N13O12/c1-5-28(4)41(47(72)59-36(23-31-25-54-26-56-31)48(73)63-20-10-14-38(63)45(70)60-37(49(74)75)22-29-11-7-6-8-12-29)62-44(69)35(21-30-15-17-32(64)18-16-30)58-46(71)40(27(2)3)61-43(68)34(13-9-19-55-50(52)53)57-42(67)33(51)24-39(65)66/h6-8,11-12,15-18,25-28,33-38,40-41,64H,5,9-10,13-14,19-24,51H2,1-4H3,(H,54,56)(H,57,67)(H,58,71)(H,59,72)(H,60,70)(H,61,68)(H,62,69)(H,65,66)(H,74,75)(H4,52,53,55)/t28-,33-,34-,35-,36-,37-,38-,40-,41-/m0/s1

SMILES Code

O=C(O)C[C@H](N)C(N[C@@H](CCC/N=C(N)\N)C(N[C@@H](C(C)C)C(N[C@@H](CC1=CC=C(O)C=C1)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC2=CN=CN2)C(N3[C@H](C(N[C@H](C(O)=O)CC4=CC=CC=C4)=O)CCC3)=O)=O)=O)=O)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,046.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: De Mello WC. Chemical Communication between Heart Cells is Disrupted by Intracellular Renin and Angiotensin II: Implications for Heart Development and Disease. Front Endocrinol (Lausanne). 2015 May 19;6:72. doi: 10.3389/fendo.2015.00072. eCollection 2015. Review. PubMed PMID: 26042086; PubMed Central PMCID: PMC4437035. 2: de Cavanagh EM, Inserra F, Ferder L. Angiotensin II blockade: how its molecular targets may signal to mitochondria and slow aging. Coincidences with calorie restriction and mTOR inhibition. Am J Physiol Heart Circ Physiol. 2015 Jul 1;309(1):H15-44. doi: 10.1152/ajpheart.00459.2014. Epub 2015 May 1. Review. PubMed PMID: 25934099. 3: Kamo T, Akazawa H, Komuro I. Pleiotropic Effects of Angiotensin II Receptor Signaling in Cardiovascular Homeostasis and Aging. Int Heart J. 2015 May 13;56(3):249-54. doi: 10.1536/ihj.14-429. Epub 2015 Apr 27. Review. PubMed PMID: 25912907. 4: Kellici TF, Tzakos AG, Mavromoustakos T. Rational drug design and synthesis of molecules targeting the angiotensin II type 1 and type 2 receptors. Molecules. 2015 Mar 2;20(3):3868-97. doi: 10.3390/molecules20033868. Review. PubMed PMID: 25738535. 5: Yang T. Crosstalk between (Pro)renin receptor and COX-2 in the renal medulla during angiotensin II-induced hypertension. Curr Opin Pharmacol. 2015 Apr;21:89-94. doi: 10.1016/j.coph.2014.12.011. Epub 2015 Feb 12. Review. PubMed PMID: 25681793; PubMed Central PMCID: PMC4445938. 6: Zucker IH, Schultz HD, Patel KP, Wang H. Modulation of angiotensin II signaling following exercise training in heart failure. Am J Physiol Heart Circ Physiol. 2015 Apr 15;308(8):H781-91. doi: 10.1152/ajpheart.00026.2015. Epub 2015 Feb 13. Review. PubMed PMID: 25681422; PubMed Central PMCID: PMC4398865. 7: Giani JF, Shah KH, Khan Z, Bernstein EA, Shen XZ, McDonough AA, Gonzalez-Villalobos RA, Bernstein KE. The intrarenal generation of angiotensin II is required for experimental hypertension. Curr Opin Pharmacol. 2015 Apr;21:73-81. doi: 10.1016/j.coph.2015.01.002. Epub 2015 Jan 21. Review. PubMed PMID: 25616034; PubMed Central PMCID: PMC4380835. 8: Hosseinimehr SJ. The use of angiotensin II receptor antagonists to increase the efficacy of radiotherapy in cancer treatment. Future Oncol. 2014 Dec;10(15):2381-90. doi: 10.2217/fon.14.177. Review. PubMed PMID: 25525846. 9: Horita S, Nakamura M, Shirai A, Yamazaki O, Satoh N, Suzuki M, Seki G. Regulatory roles of nitric oxide and angiotensin II on renal tubular transport. World J Nephrol. 2014 Nov 6;3(4):295-301. doi: 10.5527/wjn.v3.i4.295. Review. PubMed PMID: 25374825; PubMed Central PMCID: PMC4220364. 10: Smith MT, Muralidharan A. Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain. Expert Opin Ther Targets. 2015 Jan;19(1):25-35. doi: 10.1517/14728222.2014.957673. Epub 2014 Oct 15. Review. PubMed PMID: 25315162. 11: Re RN, Cook JL. Studies of intracellular angiotensin II. Methods Mol Biol. 2015;1234:1-8. doi: 10.1007/978-1-4939-1755-6_1. Review. PubMed PMID: 25304343. 12: Chang Y, Wei W. Angiotensin II in inflammation, immunity and rheumatoid arthritis. Clin Exp Immunol. 2015 Feb;179(2):137-45. doi: 10.1111/cei.12467. Review. PubMed PMID: 25302847; PubMed Central PMCID: PMC4298392. 13: Marin Garcia PJ, Marin-Castaño ME. Angiotensin II-related hypertension and eye diseases. World J Cardiol. 2014 Sep 26;6(9):968-84. doi: 10.4330/wjc.v6.i9.968. Review. PubMed PMID: 25276298; PubMed Central PMCID: PMC4176806. 14: McCarthy T. Development of EMA401 as an orally-administered, highly-selective angiotensin II type 2 receptor antagonist for the treatment of neuropathic pain. J Peripher Nerv Syst. 2014 Oct;19 Suppl 2:S13-4. doi: 10.1111/jns.12080_4. Review. PubMed PMID: 25269730. 15: Matysiak ZE, Ochędalski T, Piastowska-Ciesielska AW. The evaluation of involvement of angiotensin II, its receptors, and androgen receptor in endometrial cancer. Gynecol Endocrinol. 2015 Jan;31(1):1-6. doi: 10.3109/09513590.2014.958991. Epub 2014 Sep 18. Review. PubMed PMID: 25231075. 16: Institute for Quality and Efficiency in Health Care: Executive Summaries [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2005-. Available from http://www.ncbi.nlm.nih.gov/books/NBK237074/ PubMed PMID: 25187941. 17: Giani JF, Janjulia T, Taylor B, Bernstein EA, Shah K, Shen XZ, McDonough AA, Bernstein KE, Gonzalez-Villalobos RA. Renal generation of angiotensin II and the pathogenesis of hypertension. Curr Hypertens Rep. 2014 Sep;16(9):477. doi: 10.1007/s11906-014-0477-1. Review. PubMed PMID: 25097114; PubMed Central PMCID: PMC4277187. 18: Unal H, Karnik SS. Constitutive activity in the angiotensin II type 1 receptor: discovery and applications. Adv Pharmacol. 2014;70:155-74. doi: 10.1016/B978-0-12-417197-8.00006-7. Review. PubMed PMID: 24931196. 19: Wu J, You J, Wang S, Zhang L, Gong H, Zou Y. Insights into the activation and inhibition of angiotensin II type 1 receptor in the mechanically loaded heart. Circ J. 2014;78(6):1283-9. Epub 2014 May 12. Review. PubMed PMID: 24813328. 20: Montezano AC, Nguyen Dinh Cat A, Rios FJ, Touyz RM. Angiotensin II and vascular injury. Curr Hypertens Rep. 2014 Jun;16(6):431. doi: 10.1007/s11906-014-0431-2. Review. PubMed PMID: 24760441.